737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

Bibliographic Details
Main Authors: Brendan Curti, Igor Puzanov, Mateusz Opyrchal, Christopher J Nirschl, Mehmet A Bilen, Kristin Morris, Justin C Moser, Ildefonso Rodriguez Rivera, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items